Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

GIST pipeline

What is next, and who is running it?

Programs by company or class, across phase, filing, approval, and a stop.

A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.

Phase 1 on
ClassNone selected

Phase 1 included.

Clear filters

17 of 17 programs on this matrix

Phase 1Phase 2Phase 3FiledApprovedDiscontinued
anti-PD-L1 (with imatinib)1 program
anti-PD-L1 (with regorafenib)1 program
Class not reported1 program
DCC-3009

Registry, May 2028

Dosing n/r

Class not reported · Deciphera Pharmaceuticals

HIF-2 alpha inhibitor1 program
HSP90 inhibitor (with imatinib)1 program
KIT type I TKI plus type II TKI combination1 program
KIT-directed ADC1 program
KIT/PDGFRA TKI (type II)1 program
KIT/PDGFRA type I TKI1 program
Avapritinib

Approved

once daily, oral tablet

KIT/PDGFRA type I TKI · Blueprint Medicines

menin inhibitor (with imatinib)1 program
multi-kinase TKI2 programs
Regorafenib

Approved

once daily, days 1 to 21 of 28, oral tablet

multi-kinase TKI · Bayer

multi-kinase TKI (type II)1 program
Sunitinib

Approved

once daily, Schedule 4/2, oral capsule

multi-kinase TKI (type II) · Pfizer

selective KIT TKI2 programs
NB003

Registry, Aug 2028

twice daily, oral

selective KIT TKI · Ningbo Newbay Technology Development

switch-control KIT/PDGFRA TKI1 program
Ripretinib

Registry, Dec 2027

once daily, oral tablet

switch-control KIT/PDGFRA TKI · Deciphera Pharmaceuticals

VEGFR2 TKI (with paclitaxel)1 program